Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (DE:XE7C)
FRANKFURT:XE7C
Cardiff Oncology (XE7C) Stock Price & Analysis
2 Followers
XE7C Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.87 - €5.59
Previous Close€2.23
Volume0.00
Average Volume (3M)528.00
Market Cap
€103.08M
Enterprise Value€43.24M
Total Cash (Recent Filing)$67.19M
Total Debt (Recent Filing)$2.00M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 08, 2024EPS Estimate
-€0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,724,591
10 Day Avg. Volume0
30 Day Avg. Volume528
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.60
Price to Sales (P/S)479.97
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue70.88
Enterprise Value/Gross Profit88.60
Enterprise Value/Ebitda-1.02
Forecast
1Y Price Target
€9.64Price Target Upside332.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cardiff Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe totality of the data generated by onvansertib + chemo/bev is viewed as promising.
Financial HealthCardiff's financial resources are believed to be sufficient to provide an operational runway into 3Q25.
Regulatory MilestonesCRDF-005 trial may position onvansertib for accelerated approval based on an ORR interim analysis.
Bears Say
Clinical Trial ProgressInitial CRDF-004 trial readout now expected later due to a lower than anticipated pace of enrollment.
Clinical Trial ResultsThe randomized ONSEMBLE trial in 2L RAS+ CRC was halted, indicating a shift in company strategy.
Financial HealthCRDF reported a net loss, which may raise concerns about the company's financial sustainability.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
5.07% Other Institutional Investors
94.93% Public Companies and
Individual Investors
XE7C FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was €0.87 and its highest was €5.59 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Currently, no data Available
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Aug 08, 2024 which is in 12 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on May 02, 2024. The company reported -€0.202 earnings per share for the quarter, beating the consensus estimate of -€0.228 by €0.026.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -€0.23.
How many shares outstanding does Cardiff Oncology, Inc. have?
Currently, no data Available
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -€0.202 in its last earnings report, beating expectations of -€0.228. Following the earnings report the stock price went down -5.692%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Among the largest hedge funds holding Cardiff Oncology, Inc.’s share is Elkhorn Partners Limited Partnership. It holds Cardiff Oncology, Inc.’s shares valued at 198K.
---
Cardiff Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.64 (332.36% Upside)
€9.64 (332.36% Upside)
Blogger Sentiment
Bullish
DE:XE7C Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
76.76%
12-Months-Change
Fundamentals
Return on Equity
-51.12%
Trailing 12-Months
Asset Growth
-30.51%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
---
XE7C Earnings Call
Q1 2024
0:00 / 0:00
---
XE7C Stock 12 Month Forecast
Average Price Target
€9.64
▲(332.36% Upside)
Technical Analysis
Best Analysts Covering XE7C
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+3.17%
reiterated a buy rating 10 months ago
Copying Joel Beatty's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +3.17% per trade.
---